Azacitidine (AZA)
Azacitidine (AZA) is a pharmaceutical drug with 24 clinical trials. Currently 13 active trials ongoing. Historical success rate of 33.3%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
12
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
33.3%
1 of 3 finished
66.7%
2 ended early
13
trials recruiting
24
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia
Study of SA+X in the Treatment of Newly Diagnosed AML
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Clinical Trials (24)
A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia
Study of SA+X in the Treatment of Newly Diagnosed AML
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
FLT3-ITD Targeted Therapy in Fit AML Patients
Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
Study to Evaluate the Safety and Tolerability of EP0042
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 24